Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level
Human Vaccines and Immunotherapeutics, cilt.17, sa.6, ss.1599-1603, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 6
- Basım Tarihi: 2021
- Doi Numarası: 10.1080/21645515.2020.1846398
- Dergi Adı: Human Vaccines and Immunotherapeutics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
- Sayfa Sayıları: ss.1599-1603
- Anahtar Kelimeler: Anaphylaxis, honeybee, hymenoptera venom allergy, immunotherapy, mastocytosis, tryptase
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Mastocytosis is a rare group of disorders characterized by abnormal accumulation of mast cells in the skin, bone marrow, and internal organs. In particular, patients with systemic mastocytosis are at an increased risk of frequent and severe episodes of anaphylaxis. Hymenoptera venom allergy is the most common trigger of anaphylaxis in these patients. Immunotherapy is an effective and safe therapy recommended for patients with mastocytosis and venom allergy. Although this therapy can be administered according to different protocols, the preferred protocol for patients with mastocytosis remains unclear. Systemic side effects can occur, in particular, during the up-dosing phase of immunotherapy, making progression to the maintenance phase of therapy challenging. This case report presents the diagnosis and ultrarush immunotherapy process ended with anaphylaxis of a 33-y-old male patient with Apis mellifera allergy.